Phase III study designed to assess lapatinib in combination with chemotherapy for advanced HER2-positive gastric cancer in 2013 failed to meet the primary endpoint of improved overall survival (OS) against chemotherapy alone.
A clinical trial, conducted in 2013, evaluating the effectiveness of lapatinib combined with chemotherapy for treating advanced HER2-positive gastric cancer, did not demonstrate an advantage in overall survival when compared to chemotherapy alone.